Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22967054 | 0.92 | ROCK2 (0.53) | ROCK2ROCK1NPC1HPGDSMN1; SMN2 | |
| SCHEMBL22966755 | 0.88 | ROCK2 (0.59) | ROCK2ROCK1MEN1KMT2A | |
| SCHEMBL21217913 | 0.87 | ROCK2 (0.54) | ROCK2ROCK1NPC1 | |
| SCHEMBL24610266 | 0.86 | ROCK2 (0.47) | ROCK2ROCK1NPC1LMNAHPGD | |
| SCHEMBL21217525 | 0.86 | ROCK2 (0.58) | ROCK2ROCK1MEN1KMT2A | |
| SCHEMBL21217523 | 0.84 | ROCK2 (0.58) | ROCK2ROCK1NPC1HPGDMEN1 | |
| SCHEMBL24094235 | 0.82 | NPC1 (0.44) | ROCK2NPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL21198598 | 0.81 | ROCK2 (0.44) | ROCK2ROCK1NPC1CDK4CCND1 | |
| SCHEMBL21217529 | 0.80 | ROCK2 (0.51) | ROCK2ROCK1 | |
| SCHEMBL22966914 | 0.80 | ROCK1 (0.52) | ROCK2ROCK1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885NPC1 1742/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885NPC1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.